E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10012601 |
E.1.2 | Term | Diabetes mellitus |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To study the safety and efficacy of adding the GLP-1 analogue liraglutide (Victoza®) to current treatment with insulin and metformin in poorly regulated and overweight patients with type 2 diabetes. |
|
E.2.2 | Secondary objectives of the trial |
To study the effect of liraglutide (Victoza®) on changes in left ventricular function and mass, 24-hours mean blood pressure, glomerular filtration rate, body weight, insulin dose, 24-h glucose profiles, number of adverse events, minor and major hypoglycaemic episodes, nausea and other gastrointestinal disturbances. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
•Subjects diagnosed with type 2 diabetes •≥18 years of age •HbA1C≥8.0% •BMI≥27 kg/m2 •Treatment: Use of more than 1 unit insulin per kilogram body weight daily. Patients should have been treated with insulin and metformin for more than four months. Patients included should not be on other anti-diabetic combinations than insulin and metformin. Patients using antihypertensive, lipid-lowering, and/or anti-coagulation (acetylsalicylic acid) drugs are allowed to continue their treatment during the study period.
|
|
E.4 | Principal exclusion criteria |
•Recurrent major hypoglycaemia or hypoglycaemic unawareness as judged by the investigator •Impaired kidney function (estimated GFR below 60 ml/min/1.73m2) •Impaired liver function (p-ALAT level higher than 3 x upper normal limit) •Cancer or any clinically significant disease or disorder as judged by the investigator •History of chronic pancreatitis or idiopathic pancreatitis •History of heart disease: acute myocardial infarct, stroke, congestive heart failure, (unstable) angina pectoris. Previously unknown abnormalities in cardiac function discovered at the baseline examination may result in exclusion of the patient from the study (judged by the investigator) •Left ventricular ejection fraction < 45% •Family history of thyroid diseases •Atrial fibrillation or flutter •Intra-ventricular conduction block •Alcohol/drug abuse or in treatment with disulfiram (Antabus) at time of inclusion •Pregnant or lactating women •Fertile women not using birth control agents including oral contraceptives, gestagen injection, subdermal implantation hormonal vaginal ring, transdermal application, or intra-uterine devices •Allergic to one or more of the medications used in the study •Treatment with peroral steroids •Concomitant participation in other intervention study – judged by the investigator •Unable to understand the informed consent and the study procedures •Participation in other intervention studies at time of inclusion or within three months prior to inclusion – judged by the investigator
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Change in HbA1c from baseline to twelve weeks. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last patient, last visit (follow-up visit week 16) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |